ArticleClinical rheumatology2026
Evaluation of serum TWEAK levels and treatment response in psoriasis and psoriatic arthritis: a prospective comparative case-control study of adalimumab and methotrexate.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammatory Biomarkers for Assessing Treatment Response in Psoriasis: A Narrative Review.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPsoriasis vulgaris and psoriatic arthritis (PsA) are chronic immune-mediated diseases with systemic impact. Tumor necrosis factor (TNF)-related weak inducer of apoptosis (TWEAK) is a pro-inflammatory cytokine implicated in immune regulation and tissue remodeling, but its role in psoriatic disease remains incompletely understood.
methodsThis prospective case-control study included 100 subjects: 30 psoriasis patients receiving adalimumab, 30 PsA patients receiving methotrexate, and 40 healthy controls. Serum TWEAK was measured by ELISA at baseline and after 24 weeks. PASI and DAPSA scores were evaluated at both visits.
resultsBaseline TWEAK was higher in psoriasis (3.85 ± 0.62 ng/mL) and PsA patients (4.12 ± 0.71 ng/mL) than in controls (1.95 ± 0.54 ng/mL, p < 0.001). After 24 weeks, TWEAK decreased in both the adalimumab (2.21 ± 0.49 ng/mL) and methotrexate groups (2.67 ± 0.53 ng/mL, p < 0.001). Clinical improvement assessed by PASI and DAPSA paralleled this biochemical reduction, suggesting that TWEAK may serve as a biomarker of treatment response. TWEAK showed a stronger correlation with PASI after 24 weeks of treatment than with DAPSA.
conclusionElevated TWEAK reflects psoriasis and PsA activity. Adalimumab and methotrexate reduce TWEAK alongside clinical improvement, supporting its potential as a biomarker for treatment monitoring. Key Points • Serum TWEAK levels were substantially elevated in psoriasis and psoriatic arthritis patients in comparison to controls. • TWEAK levels decreased following treatment with methotrexate and adalimumab. • Clinical improvement and disease activity scores were positively correlated with a decrease in TWEAK levels. • TWEAK may be a valuable biomarker for the monitoring of treatment response in psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.